The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
What Is The Projected Increase In Market Value Of The Neuropathic Pain Market During 2026–2030?
The neuropathic pain market has shown substantial growth in recent years. It is anticipated to expand from $5.78 billion in 2025 to $6.2 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 7.3%. This historical growth can be attributed to factors such as the rising prevalence of diabetes, the early adoption of antidepressants and anticonvulsants, increased awareness of neuropathic pain conditions, the development of opioid-based treatments, and the initial use of imaging for diagnosis.
The neuropathic pain market is projected for substantial expansion over the next few years, set to reach $8.48 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 8.1%. This anticipated growth during the forecast period stems from a growing inclination towards non-opioid treatments, an increasing need for personalized pain management, the broader use of complementary therapies, rising investments in diagnostic innovations, and the development of advanced multimodal treatment solutions. Significant trends observed in this period include the rising adoption of multimodal therapy approaches, increasing demand for non-opioid pain relief, the growing integration of physical and psychological therapies, an expansion of early diagnosis through imaging techniques, and an elevated focus on diabetic neuropathy treatment.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12922&type=smp
Which Drivers Are Supporting The Neuropathic Pain Market Growth?
The increasing incidence of chronic pain is projected to drive expansion within the neuropathic pain market in the future. This condition is characterized by persistent discomfort that endures for at least three months, affecting a considerable segment of the populace and markedly diminishing their quality of life. The surge in chronic pain incidents stems from factors including aging populations, nerve damage, and long-term health issues such as diabetes. Treatments for neuropathic pain contribute to public health by addressing nerve dysfunction, alleviating symptoms, and enhancing patients’ everyday activities. As an illustration, in November 2024, figures released by the Centers for Disease Control and Prevention (CDC), the US national health protection agency, indicated that in 2023, adult populations had a 24.3% prevalence of chronic pain and an 8.5% prevalence of high-impact chronic pain, which equated to 34.9% among individuals experiencing chronic pain, with women, American Indian and Alaska Native adults, and those aged 65 years and older demonstrating particularly elevated rates. Consequently, the growing prevalence of chronic pain is a key factor boosting the neuropathic pain market.
How Is The Neuropathic Pain Market Broken Down By Segment Categories?
The neuropathic pain market covered in this report is segmented –
1) By Treatment: Medications, Multimodal Therapy
2) By Diagnosis: Imaging, Blood Tests And Physical Examination
3) By Indication: Diabetic Neuropathy, Spinal Stenosis, Chemotherapy-Induced Peripheral Neuropathy, Other Indications
4) By End User: Hospitals, Clinics, Home Healthcare, Ambulatory Surgical Centers, Other End Users
Subsegments:
1) By Medications: Anticonvulsants, Antidepressants, Opioids, Topical Treatments, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
2) By Multimodal Therapy: Combination Of Medications, Physical Therapy, Psychological Therapy, Lifestyle Modifications, Complementary Therapies
Which Trends Are Expected To Impact The Neuropathic Pain Market?
Leading companies in the neuropathic pain market are integrating artificial intelligence technologies for advanced diagnostics, personalized treatment strategies, real-time patient monitoring, new drug discovery, and data-driven insights, all aimed at improving patient outcomes and refining pain management approaches. For instance, in March 2023, Nevro Corp., a US-based medical device company, introduced the Senza HFX iQ spinal cord stimulation (SCS) system. This innovative technology employs artificial intelligence (AI) to customize pain relief for individual patients. The system, which includes the HFX iQ Implantable Pulse Generator (IPG), HFX Trial Stimulator, Charger, and HFX App, is designed to treat non-surgical back pain and painful diabetic neuropathy by adapting to patient responses and feedback. It utilizes a unique algorithm built on extensive patient data and allows patients to adjust their pain relief program using a smartphone application. The system’s digital environment permits data collection and potential future updates. The technology aims to enhance the consistency and personalization of pain relief, signifying a major advancement in SCS therapy.
Which Players Are Present In The Neuropathic Pain Market Space?
Major companies operating in the neuropathic pain market are Pfizer Inc., Johnson & Johnson Private Limited, Sanofi S.A., Bristol‑Myers Squibb Company, Abbott Laboratories, GlaxoSmithKline Plc, Medtronic Inc., Eli Lilly and Company, Teva Pharmaceutical Industries Ltd, Boston Scientific Corporation, Sun Pharmaceutical Industries Ltd., Mallinckrodt Pharmaceuticals, Grünenthal GmbH, Lupin Ltd., Nevro Corp., InvaGen Pharmaceuticals Inc, Centaur Pharmaceuticals Pvt Ltd., Stimwave LLC, Novartis AG, Astellas Pharma Inc., Vertex Pharmaceuticals Incorporated, Assertio Therapeutics Inc, NeuroMetrix Inc, OMRON Healthcare Co Ltd
Get The Full Neuropathic Pain Market Report:
https://www.thebusinessresearchcompany.com/report/neuropathic-pain-global-market-report
Which Region Holds The Highest Market Share In The Neuropathic Pain Market?
North America was the largest region in the neuropathic pain market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neuropathic pain market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Neuropathic Pain Market Report For Competitive Insights:
https://www.thebusinessresearchcompany.com/report/neuropathic-pain-global-market-report
Browse Through More Reports Similar to the Global Neuropathic Pain Market 2026, By The Business Research Company
Optic Atrophy Management Market Report 2026
https://www.thebusinessresearchcompany.com/report/optic-atrophy-management-global-market-report
Peripheral Neuropathy Market Report
https://www.thebusinessresearchcompany.com/report/peripheral-neuropathy-global-market-report
Retinal Disorder Treatment Market Report
https://www.thebusinessresearchcompany.com/report/retinal-disorder-treatment-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model